Minai-Azary Jennifer Lynn 4

What Happened
Jennifer Minai-Azary, Chief Financial Officer of Context Therapeutics (CNTX), received a grant/award of derivative securities covering 275,000 shares on February 19, 2026. The filing reports an acquisition at $0.00 (reported value $0) — this is a time-based equity award (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: February 19, 2026; Form 4 filed February 23, 2026 (timely).
• Instrument: Derivative award (option/award) for 275,000 shares; reported price/exercise $0.00; reported value $0.
• Vesting (footnote): 25% vests on February 19, 2027; remaining 75% vests in equal monthly installments over the next three years, subject to continued service.
• Shares owned after transaction: Not disclosed in this Form 4.
• No indication in the filing of an immediate sale, tax withholding, 10b5-1 plan, or late filing.

Context
This was a time‑based executive equity award intended to vest over four years (standard for incentive grants). Because it’s a derivative/time-vested award, it does not represent immediately available cash or marketed shares; vested portions would become exercisable according to the schedule. Such grants are common as part of executive compensation and are informational for investors tracking insider alignment with company performance.